Akebia Therapeutics Inc (AKBA)

[Blutribe]

part 2 Reasons we like this name:

1) They are treating kidney disease, an indication on our "hot list" as it falls into the category of "bullish on aging population stocks"
2) The chart is at the latter stage of a bullish inverted head and shoulders pattern, and if the stock clears through $13.00 it could head to $30+
3) Insiders bought $4,200,000 worth of stock in the past 6 months
4) 17% of the share float is short and the stock's options have a put call ratio of 2.75 - both are off the charts bullish -